Skip to main content

Table 1 Clinical features, underlying diseases, and therapy of the two groups of patients

From: Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

  Group R number [percentage (%)] Group C number [percentage (%)]
Clinical features Fever ≥38.5 °C 11 (100) 11 (100)
Splenomegaly 11 (100) 11 (100)
Cytopenias 11 (100) 10 (90.91)
Hypofibrinogenemia/
Hypertriglyceridemia
11 (100) 10 (90.91)
Elevated ferritin 11 (100) 11 (100)
Hemophagocytosis 7 (63.64) 7 (63.64)
Low or absent NK-cell activity 4 (36.36) 7 (63.64)
Elevated soluble CD25 7 (63.64) 7 (63.64)
Underlying diseases Infection 8 (72.73) 4 (36.36)
Juvenile idiopathic arthritis (systemic type) 2 (18.18) 6 (54.55)
Kawasaki disease 1 (9.10) /
Systemic lupus erythematosus / 1 (9.10)
Therapy
(Group R: before ruxolitinib)
HLH-04
MP and IVIG
4 (36.36)
3 (27.27)
6 (54.55)
5 (45.45)
IVIG 4 (36.36) /
  1. NK-cell natural killer cell; HLH hemophagocytic lymphohistiocytosis; MP methylprednisolone; IVIG intravenous immunoglobulin; Group R ruxolitinib-treated group; Group C control group treated with conventional therapy